DPC 817: A cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 5, 2002, Pages 1394-1401

  Schinazi, Raymond F ^a   Mellors, John ^a   Bazmi, Holly ^a   Diamond, Sharon ^a   Garber, Sena ^a   Gallagher, Karen ^a   Geleziunas, Romas ^a   Klabe, Ron ^a   Pierce, Michael ^a   Rayner, Marlene ^a   Wu, Jing Tao ^a   Zhang, Hangchun ^a   Hammond, Jennifer ^a   Bacheler, Lee ^a   Manion, Douglas J ^a   Otto, Michael J ^a   Stuyver, Lieven ^a   Trainor, George ^a   Liotta, Dennis C ^a   Erickson Viitanen, Susan ^a  

^a PHARMASSET INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE DERIVATIVE; EFAVIRENZ; ELVUCITABINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG UPTAKE; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; ANTI-HIV AGENTS; CYTIDINE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MACACA MULATTA; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; ZALCITABINE; ZIDOVUDINE;

EID: 0036232997     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.5.1394-1401.2002     Document Type: Article

References (35)

1. An assay for HIV RNA in infected cell lysates, and its use for rapid evaluation of antiviral efficacy
2. In vitro selection of mutations in the human immunodeficiency virus type I reverse transcriptase that decrease susceptibility to (-)-βp-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine
3. Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates
4. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA panel
5. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: The OzCombo 1 study
6. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-HIV compound, 2′3′-dideoxy-cytidine
7. Synthesis and comparative evaluation of two antiviral agents: Beta-L-Fd4C and beta-D-Fd4C
8. Kinetic interaction of the diphosphates of 9-(2-phosphonyl methoxyethyl) adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases α, ↑, and γ
9. Incorporation of selected nucleoside phosphonates and anti-human immunodeficiency virus nucleotide analogues into DNA by human DNA polymerases β, β, and γ
10. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy
11. Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients
12. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells
13. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain terminated DNA synthesis
14. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
15. Resistance to antiretroviral drugs-an emerging problem
16. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
17. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus
18. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild types and protease inhibitor resistant mutants of HIV
19. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity
20. The retroviral enzymes
21. Pharmacokinetics of the antiviral agent β-D-2′,3′-didehydro-2′, 3′-dideoxy-5-fluorocytidine in rhesus monkeys
22. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1
23. Pharmacokinetic evaluation of drug interactions with zidovudine: Probenecid and zidovudine in monkeys
24. Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies
25. Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals
26. Metabolism, mitochondrial uptake and toxicity of 2′,3′-dideoxycytidine
27. Activities of 3′-azido-3′-deoxythymidine nucleotide dimers in primary lymphocytes infected with human imunodeficiency virus type 1
28. Mutations in retroviral genes associated with drug resistance: 2000-2001 Update
29. Synthesis and biological evaluation of 2′,3′-dide-hydro-2′3′-dideoxy-5-fluorocytidine (D4FC) analogues: Discovery of carbo-cyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase
30. Synthesis and anti-HIV activity of a series of 2-indolinones and related analogs
31. Pharmacological considerations in antiretroviral therapy
32. Intracellular metabolism of 3′azidothymidine in isolated human peripheral blood mononuclear cells
33. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues
34. Viral dynamics in human immunodeficiency virus type I infection
35. HIV therapy: Managing resistance